Wereport a rare case of pseudotumor cerebri associated with all-trans retinoic acid (ATRA) treatment of acute promyelocytic leukemia (APL). An 18-year-old male was admitted to our hospital complaining of palpitations and shortness of breath; he was found to have APL. The administration of ATRA and chemotherapy was started. After 23 days, he complained of nausea, headache and double vision. Computed tomography and magnetic resonance imaging of the head showed no intracranial abnormalities. Bilateral papilledema, a symptom of increased intracranial pressure, wasnoted. A diagnosis of pseudotumor cerebri was made.Symptoms were improved by administration of glycerin and the discontinuation of ATRA. After 29 days, a complete remission wasachieved. (Internal Medicine 37: 546-549, 1998) 
Introduction
All-trans retinoic acid (ATRA) is commonly used in treating patients with acute promyelocytic leukemia (APL). This agent has induced a high incidence of complete remission in newly diagnosed patients with APL (1-5). Response is marked by the differentiation of leukemic promyelocytes into neutrophils. No bone marrowaplasia is observed, and a rapid improvement in the hemostatic disorder is obtained (1-5). However, in some patients, ATRA therapy leads to hyperleukocytosis and the retinoic acid syndrome characterized by fever, respiratory distress, weight gain, edema of lower extremities, pleural effusion, pericardial effusion, and hypotension (6). In addition, Vitamin A toxicity may lead to pseudotumor cerebri which is characterized by headache, nausea, papilledema, and diplopia (7).
Wedescribe a rare case of pseudotumor cerebri associated with ATRA treatment of APL during induction therapy.
Case Report
An 18-year-old Japanese man was admitted to our hospital with palpitations and shortness of breath on January 1 1, 1996. Physical examination on admission revealed conjunctival pallor and purpura of the extremities. Laboratory findings on admission are shown in Table 1 . Complete blood count disclosed a white blood cell count of 1.6xlO3/jnl with 25% blasts or promyelocytes, hemoglobin of 6.7 g/dl, and platelet count of 1 1x1O3/jliL The findings of coagulation tests indicated the presence of disseminated intravascular coagulopathy (DIC).
Blood chemistry values were normal except for the elevation of blood urea nitrogen (BUN), lactate dehydrogenase (LDH) and aspartate aminotransferase (AST). A bone marrow aspirate revealed a markedly hypercellular marrow with 85% blasts and promyelocytes. Most leukemic cells were positive for myeloperoxidase staining, CD 13 and CD 33. Auer bodies and azure granules were observed in the cytoplasm of the leukemic cells. Cytogenetic analysis showed normal karyotype. PML/RAR-a mRNA rearrangement was detected in bone marrow cells using the reverse transcriptase polymerase chain reaction method (Fig. 1) . Under the diagnosis of APL, ATRA (45 mg/m2/day) was administered orally beginning January 1 1 , 1996. The patient' s clinical course is summarized in Fig. 2 . Because the number of leukemic cells had increased to 1,710/jj.l on day 2 of therapy, chemotherapy consisting of daunorubicin (40 mg/m2) for 3 days and behenoyl cytosine arabinoside (200 mg/m2) for 5 days was administered to prevent the retinoic acid syndrome. Following the treatment, the number of leukemic cells gradually decreased and the DIC improved rapidly. curred. On day 23 of ATRA therapy, the patient complained of nausea, headache and double vision. Computed tomography and magnetic resonance imaging of the head showed no intracranial abnormalities. Bilateral papilledema was noted (Fig. 3) The pathogenesis ofpseudotumor cerebri is unknown.Spector et al (7) production of CSF and alters the lipid constituents of the arachnoid villi, disrupting the normal transport systems and impeding the absorption of CSF at the arachnoid villi. The reason why our patient developed pseudotumor cerebri is not clear, but we believe that, as a young patient with APL, he was more sensitive to the effects of ATRA on the central nervous system. In conclusion, although pseudotumor cerebri is a rare complication in adult APL, it is important to differentiate it from cerebral hemorrhage or CNS leukemia, and to discontinue ATRA or administer steroid hormones or glycerin as soon as possible. 
